WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib 06 March 2011
New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin 13 February 2011
Pfizer To Acquire Ferrosan's Consumer Healthcare Business 07 February 2011
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan 06 February 2011
Pfizer Reports Fourth-Quarter and Full-Year 2010 Results 01 February 2011
Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc. 31 January 2011
Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older 22 December 2010
Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc. 15 December 2010
Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine 12 December 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib 06 December 2010
Pfizer Launches Global Centers for Therapeutic Innovation 18 November 2010
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity 15 November 2010
Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent 09 November 2010
Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion 03 November 2010
Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066) 28 October 2010
Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil 22 October 2010
Biocon and Pfizer Enter Into Global Commercialization Agreement 20 October 2010
Results from a national survey of Alzheimer's Disease 15 October 2010
Pfizer to Acquire King Pharmaceuticals, Inc. 13 October 2010
Updated Pfizer Pipeline Focuses on Value, Unmet Medical Need 28 September 2010
  • Start
  • Prev
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next
  • End

Business & Industry

  • Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
  • Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
  • Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare

Research & Development

  • COVAX announces new agreement, plans for first deliveries
  • Obesity, impaired metabolic health and COVID-19
  • COVID-19 has multiple faces
  • Metformin use reduces risk of death for patients with COVID-19 and diabetes
  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer completes acquisition of Therachon

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.